Acetylcholinesterase (AChE) remains a highly viable target for the symptomatic improvement in Alzheimer's disease (AD) because cholinergic deficit is a consistent and early finding in AD. Here, ACHE is linked to early-onset autosomal dominant Alzheimer disease.